Cell Therapy and Myocardial Recovery in Heart Failure Patients Undergoing Left Ventricular Assist Device Support

Patient inclusion criteria will consist of all of the following: 1. non-ischemic dilated cardiomyopathy 2. patient accepted for LVAD support 3. optimal (or maximal tolerable therapy) heart failure ≥ 2 months 4. age 18-65 years 5. ability to provide informed consent Patient exclusion criteria will consist of any of the following: 1. ischemic cardiomyopathy 2. Cardiomyopathy with a reversible cause that has not been treated e.g. thyroid disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium toxicity \& chronic uncontrolled tachycardia. 3. Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's progressive muscular dystrophy. 4. ongoing or recent (less than 1 month) infection 5. acute multi-organ failure 6. clinically significant anemia (Hb \< 10 g/dL) 7. clinically significant leukopenia (L \< 2 x 109/L) or leukocytosis (L \> 14 x 109/L) 8. clinically significant thrombocytopenia (TRC \< 50 x 109/L) 9. known disorders of hemostasis that can not be corrected 10. history of any thromboembolic complications 11. chronic kidney disease (higher than stage III) 12. chronic liver disease (Child B or C) 13. diminished functional capacity for other reasons such as COPD, moderate or severe claudications, severe musculosceletal system pain or morbid obesity (BMI \> 35 kg/m2) 14. aortic stenosis (AVA \< 1.3 cm2) or ocluded aortic valve 15. artificial (mechanical or biological) aortic valve 16. patients with reduced immune response 17. history of limphoprolipherative disorders or malignancy within 5 years 18. left ventricular thrombus 19. participation in another interventional clinical trial 20. life expectancy less than 12 months 21. known hypersensitivity to DMSO, penicillin or streptomycin